Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Decaens

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
Hepatology (Baltimore, Md.)|December 28, 2017
Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceMarianne Ziol, Nicolas Poté, Giuliana Amaddeo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 7, 2024
Recipient age influences survival after liver transplant: Results of the French national cohort 2007-2017Lea Lerosey, Elea Ksiasek, Michal Abrahamowicz, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 20, 2026
Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive managementEleonora De Martin, Teresa Maria Antonini, Thomas Uguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
JHEP Reports : Innovation in Hepatology|December 24, 2024
Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptorsCharlotte A Hernandez, Claire Verzeroli, Armando Andres Roca-Suarez, et al.
European Journal of Gastroenterology & Hepatology|August 14, 2023
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohortEric Nguyen-Khac, Pierre Nahon, Olivier Ganry, et al.
Ebiomedicine|November 5, 2021
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinomaMonika Lewinska, Alvaro Santos-Laso, Enara Arretxe, et al.
Journal of Hepatology|March 23, 2024
Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC studyCatherine Lamarque, Lauriane Segaux, Philippe Bachellier, et al.
Science Advances|September 6, 2023
Nucleoside diphosphate kinases 1 and 2 regulate a protective liver response to a high-fat dietDomenico Iuso, Isabel Garcia-Saez, Yohann Couté, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Hepatology (Baltimore, Md.)|December 28, 2017
Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceMarianne Ziol, Nicolas Poté, Giuliana Amaddeo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 7, 2024
Recipient age influences survival after liver transplant: Results of the French national cohort 2007-2017Lea Lerosey, Elea Ksiasek, Michal Abrahamowicz, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 20, 2026
Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive managementEleonora De Martin, Teresa Maria Antonini, Thomas Uguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
JHEP Reports : Innovation in Hepatology|December 24, 2024
Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptorsCharlotte A Hernandez, Claire Verzeroli, Armando Andres Roca-Suarez, et al.
European Journal of Gastroenterology & Hepatology|August 14, 2023
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohortEric Nguyen-Khac, Pierre Nahon, Olivier Ganry, et al.
Ebiomedicine|November 5, 2021
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinomaMonika Lewinska, Alvaro Santos-Laso, Enara Arretxe, et al.
Journal of Hepatology|March 23, 2024
Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC studyCatherine Lamarque, Lauriane Segaux, Philippe Bachellier, et al.
Science Advances|September 6, 2023
Nucleoside diphosphate kinases 1 and 2 regulate a protective liver response to a high-fat dietDomenico Iuso, Isabel Garcia-Saez, Yohann Couté, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Pageof 13